Pharmaceutical News

RSS

Swedish agency approves Medivir's Xerclear for treatment of cold sores

The Swedish Medical Products Agency has now approved Xerclear™ for treatment of cold sores. It is the first and only topical treatment that has been demonstrated to prevent the incidence of cold sores and shorten healing-times. Xerclear™ will be available from pharmacies in the first half-year 2010.

21 Dec 2009

EMEA grants orphan drug designation for pixantrone in Europe

Cell Therapeutics, Inc. ("CTI") announced today that the European Medicines Agency (EMEA) has granted pixantrone orphan drug designation for the treatment of DLBCL which accounts for about 80% of aggressive non-Hodgkin's lymphoma.

21 Dec 2009

Ethisphere names Pfizer whistleblower as 2009's most influential person in business ethics

John Kopchinski, the whistleblower whom Phillips & Cohen LLP represented in a successful, record-setting "qui tam" case against Pfizer Inc., has been named as the most influential person in business ethics for 2009.

19 Dec 2009

Medical liability concerns lead to overprescription of antibiotics

A new study led by a team of researchers at New York Medical College suggests that that medical liability concerns may be playing a role in the increase of MRSA in healthcare settings by encouraging clinicians to prescribe antibiotics more often and more broadly than clinical circumstances and evidence-based guidelines warrant. The study appeared in the September-October issue of the American Journal of Therapeutics.

19 Dec 2009

CPSC announces voluntary recall of Vicks Dayquil Cold & Flu Liquicaps

The U.S. Consumer Product Safety Commission, in cooperation with the firm named below, today announced a voluntary recall of the following consumer product. Consumers should stop using the recalled products immediately unless otherwise instructed.

19 Dec 2009

Akorn exits vaccine distribution business

Akorn, Inc. today announced that it failed to reach an amicable resolution to a longer term and strategic business arrangement with the supplier of its Tetanus Diphtheria (“Td”) vaccine and as a result will be exiting the business. The existing supply agreement will end on March 14, 2010. The company previously announced its intent to exit the distribution of flu vaccines.

19 Dec 2009

MinuteClinic medical clinics in select CVS/pharmacy stores offer H1N1 vaccinations

MinuteClinic medical clinics in select CVS/pharmacy stores throughout Maryland, North Carolina and Tennessee are now offering H1N1 vaccinations on demand seven days a week with no appointment necessary.

19 Dec 2009

158 of American Oriental Bioengineering's drugs included in China's 2009 NIC

American Oriental Bioengineering, Inc., ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that 158 of the Company's drugs have been included in China's National (Medical) Insurance Catalog (the "2009 NIC").

19 Dec 2009

Sanofi Pasteur pediatric H1N1 vaccine recall: No danger and no need of an extra dose

There is no danger if your child received the H1N1 vaccine that was recalled by Sanofi Pasteur. That is the information being provided to anyone calling the NJ Poison Control Center's hotline, according to Bruce Ruck, Pharm.D., Director of Drug Information and Professional Education. The public should be reassured that this recall took place because specific lots were found to be slightly weaker than they should have been.

19 Dec 2009

McNeil Consumer Healthcare announces recall of TYLENOL in bottles with red EZ-OPEN CAP

In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is expanding its voluntary recall to include all available product lots of TYLENOL® Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP (Full list of lot numbers provided below).

18 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Cangene Corporation today reports that it has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use ("CHMP") regarding the immunoprophylaxis indication of Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin).

18 Dec 2009

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

Nu Skin Enterprises launches the new ageLOC Future Serum

Nu Skin Enterprises, Inc. introduced the new ageLOC Future Serum to more than 10,000 sales representatives at its launch event in Japan. Japanese distributors were eager to be in the first market to fully launch one of the company's new ageLOC skin care products that targets the sources of aging by resetting youth gene clusters to a more youthful pattern. The ageLOC products are marketed as 'genLOC' in Japan.

18 Dec 2009

Jubilant Organosys announces new facility for Niacinamide and 3-Cyanopyridine

Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, announced today that it is setting up Niacinamide and 3-Cyanopyridine plant of 10,000 TPA each, expected to be ready by end of 2010.

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.

18 Dec 2009

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

18 Dec 2009

Nutricia North America improves its packaging with BPA-free lining for all powdered products

Nutricia North America, a manufacturer of medical foods and specialized infant formulas such as Neocate®, announced today that it has begun packaging its powdered medical foods and specialized infant formulas in cans with BPA-free lining.

18 Dec 2009

Pharmaceutical News

Swedish agency approves Medivir's Xerclear for treatment of cold sores

EMEA grants orphan drug designation for pixantrone in Europe

Ethisphere names Pfizer whistleblower as 2009's most influential person in business ethics

Medical liability concerns lead to overprescription of antibiotics

CPSC announces voluntary recall of Vicks Dayquil Cold & Flu Liquicaps

Akorn exits vaccine distribution business

MinuteClinic medical clinics in select CVS/pharmacy stores offer H1N1 vaccinations

158 of American Oriental Bioengineering's drugs included in China's 2009 NIC

Sanofi Pasteur pediatric H1N1 vaccine recall: No danger and no need of an extra dose

McNeil Consumer Healthcare announces recall of TYLENOL in bottles with red EZ-OPEN CAP

GSK receives European CHMP positive opinion for Revolade

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

Nu Skin Enterprises launches the new ageLOC Future Serum

Jubilant Organosys announces new facility for Niacinamide and 3-Cyanopyridine

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Nutricia North America improves its packaging with BPA-free lining for all powdered products

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News